Acute Gout Flare Market Analysis, Epidemiology, Treatment, Companies, Pipeline, Drugs and Competitive Analysis by DelveInsight

Acute Gout Flare Market

DelveInsight’s “Acute gout Flare Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acute gout Flare , historical and forecasted epidemiology as well as the Acute gout Flare market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Some key facts of Acute gout Flare Market Report are:

As per National Health and Nutrition Examination Survey (NHANES), the prevalence of gout was 3.9% among US adults, which corresponds to an estimated 9.2 million adults with gout in 2015–2016.
The EPISER 2016 (Study of the prevalence of rheumatic diseases in adult population) study in Spain, says that gout has a prevalence of more than 2.6% in Spanish adult population
Gout accounts for approximately 7 million ambulatory visits in the United States annually at a cost of nearly $1 billion
Based on gender, Gout is three times more prevalent in males than females.
The incidence of hyperuricemia, a primary risk factor for Gout, is increasing in all western countries
As per DelveInsight’s analysis, it is estimated that older adults are at increased risk for Gout, compared to other age groups.


Request for Sample Report:


Scope of the Acute gout Flare Market Report

The report covers the descriptive overview of Acute gout Flare , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Acute gout Flare epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Acute gout Flare are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Acute gout Flare market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute gout Flare market


Acute gout Flare Risk factors include genetics, age, sex, and diet. These factors may contribute to a high serum uric acid level, which is currently defined as a value of at least 6.8 mg per dL (405 μmol per L). Hyperuricemia is a primary risk factor for gout. Gout is more prevalent in males than females; It affects adults more than 60 years of age than younger population; Genetic pre-disposition for Gout, plays a vital role in disease progression. Excessive consumption of foods such as red meat, seafood, sugar-sweetened soft drinks, fructose and alcohol increase the risk of developing hyperuricemia.


Gout is an inflammatory arthritis that is triggered by the crystallization of monosodium urate (MSU) inside the joints and is preceded by hyperuricemia. Gout progresses in 4 stages: Asymptomatic hyperuriceamia, Acute gout flare/attack, intercritical period, and if left untreated the disease reaches the Chronic tophaceous gout. In general, Gout is a manageable disease, if diagnosed and treated properly.

Gout flares lead to substantial morbidity by causing severe pain, reduced quality of life, decreased physical function as the patients experience symptoms such as severe pain and inflammation in one or more joints. Epidemiology studies shoe that Gout has become more prevalent over the past few decades, affecting over 3% of adults in the US.


Request for Sample Report:


Acute gout Flare Companies covered:

Olatec Therapeutics
Selecta Biosciences
JW Pharmaceuticals
Savient Pharmaceuticals
Takeda Pharmaceutical
Teijin Pharma Ltd
Regeneron Pharmaceuticals
And Many Others


Acute gout Flare Therapies:

And Many Others


Request for Sample Report:


Table of Contents:

1. Key Insights

2. Executive Summary of Acute gout Flare

3. Competitive Intelligence Analysis for Acute gout Flare

4. Acute gout Flare: Market Overview at a Glance

4.1. Acute gout Flare Total Market Share (%) Distribution in 2017

4.2. Acute gout Flare Total Market Share (%) Distribution in 2030

5. Acute gout Flare: Disease Background and Overview

6. Patient Journey

7. Acute gout Flare Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Acute gout Flare Treatment and Management

8.2. Acute gout Flare Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Acute gout Flare Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Acute gout Flare: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Acute gout Flare

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States